Literature DB >> 23276957

MicroRNA role in thyroid cancer pathogenesis.

Xiaoping Zhang1, Haian Mao, Zhongwei Lv.   

Abstract

MicroRNAs (miRNAs) are a class of endogenous, non-coding RNAs approximately 22 nucleotides in length that negatively regulate translation of the protein-coding genes. As such, miRNAs are fundamental mediators of cellular differentiation, proliferation, and survival. Each miRNA may functionally interact with a multitude of target genes to exert various effects on normal physiology to support human health or pathological processes leading to disease conditions, such as cancer. Genome-wide analyses have generated specific miRNA profiles of thyroid cancers (TCs) and identified the up- and down-regulated miRNAs related to various carcinogenesis stages and prognoses. Here, we summarize the recent knowledge on aberrant miRNA expression in the various TCs, including papillary, follicular, and other rare types. In addition, we discuss the significance of miRNA profiles and individual miRNAs in the diagnosis, treatment, and prognosis of these tumors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23276957     DOI: 10.2741/4135

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  13 in total

1.  MicroRNA-215 is a potential prognostic marker for cervical cancer.

Authors:  Hua Liang; Yan Li; Ruo-Yu Luo; Fu-Jin Shen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-04-08

Review 2.  Prognostic biomarkers in thyroid cancer.

Authors:  Paula Soares; Ricardo Celestino; Miguel Melo; Elsa Fonseca; Manuel Sobrinho-Simões
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

3.  Cancer stem cells as a potential therapeutic target in thyroid carcinoma.

Authors:  Luisa Vicari; Cristina Colarossi; Dario Giuffrida; Ruggero De Maria; Lorenzo Memeo
Journal:  Oncol Lett       Date:  2016-08-02       Impact factor: 2.967

4.  Long non-coding RNA DIO3OS/let-7d/NF-κB2 axis regulates cells proliferation and metastasis of thyroid cancer cells.

Authors:  Mingming Wang; Jin Li; Zhongkun Zuo; Chutong Ren; Tenglong Tang; Chen Long; Yi Gong; Fei Ye; Zhihong Wang; Jiangsheng Huang
Journal:  J Cell Commun Signal       Date:  2020-10-15       Impact factor: 5.782

5.  Restoration of Brain Acid Soluble Protein 1 Inhibits Proliferation and Migration of Thyroid Cancer Cells.

Authors:  Run-Sheng Guo; Yue Yu; Jun Chen; Yue-Yu Chen; Na Shen; Ming Qiu
Journal:  Chin Med J (Engl)       Date:  2016-06-20       Impact factor: 2.628

6.  LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling.

Authors:  Hua Liu; Haoyu Deng; Yajie Zhao; Can Li; Yu Liang
Journal:  J Exp Clin Cancer Res       Date:  2018-11-21

7.  MicroRNA-675 directly targets MAPK1 to suppress the oncogenicity of papillary thyroid cancer and is sponged by long non-coding RNA RMRP.

Authors:  Junyi Wang; Tiantian Xiao; Ming Zhao
Journal:  Onco Targets Ther       Date:  2019-09-06       Impact factor: 4.147

8.  Long Noncoding RNA LINC00460 Modulates MMP-9 to Promote Cell Proliferation, Invasion and Apoptosis by Targeting miR-539 in Papillary Thyroid Cancer.

Authors:  Xian Zou; Zhi Heng Guo; Qun Li; Pei Song Wang
Journal:  Cancer Manag Res       Date:  2020-01-09       Impact factor: 3.989

9.  MiR-4269 suppresses the tumorigenesis and development of pancreatic cancer by targeting ZEB1/OTX1 pathway.

Authors:  Xin Sui; Zhenghui Sui
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

10.  MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib.

Authors:  Sandra Lassalle; Joséphine Zangari; Alexandra Popa; Marius Ilie; Véronique Hofman; Elodie Long; Martine Patey; Frédérique Tissier; Geneviève Belléannée; Hélène Trouette; Bogdan Catargi; Isabelle Peyrottes; Jean-Louis Sadoul; Olivier Bordone; Christelle Bonnetaud; Catherine Butori; Alexandre Bozec; Nicolas Guevara; José Santini; Imène Sarah Hénaoui; Géraldine Lemaire; Olivier Blanck; Philippe Vielh; Pascal Barbry; Bernard Mari; Patrick Brest; Paul Hofman
Journal:  Oncotarget       Date:  2016-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.